AIDS. 2001 Feb 16;15(3):309-20. doi: 10.1097/00002030-200102160-00003.
Viral drug susceptibility is associated with virologic response to new treatments. Standardized drug resistance tests are now available, and data from some clinical trials suggest that the use of drug resistance testing may be associated with improved virologic outcome. However, drug resistance testing is complex in terms of performance, interpretation and clinical application. HIV-1 drug resistance testing is used across Europe in patient management, but not in a consistent manner. This is due to differences in the national approaches to treatment, treatment management and reimbursement, as well as availability of tests. National guidelines only exist in some countries. In addition, the laboratory quality assurance and quality control standards are not applied uniformly. The EuroGuidelines Group was established to formulate clinical as well as laboratory guidelines for the use of HIV-1 drug resistance testing that are specific for the European setting. The group is comprised of academic clinicians and virologists, scientist from the industry and representatives of the patient community. The panel of experts will review these guidelines and update them on a yearly basis as new scientific evidence becomes available.
病毒药物敏感性与新治疗方法的病毒学反应相关。目前已有标准化的耐药性检测方法，一些临床试验数据表明，使用耐药性检测可能会改善病毒学结果。然而，耐药性检测在操作、解读和临床应用方面都很复杂。在欧洲，HIV-1耐药性检测用于患者管理，但方式并不一致。这是由于各国在治疗方法、治疗管理和报销以及检测可用性方面存在差异。只有一些国家存在国家指南。此外，实验室质量保证和质量控制标准并未统一应用。欧洲指南小组的成立是为了制定针对欧洲情况的HIV-1耐药性检测临床和实验室指南。该小组由学术临床医生和病毒学家、行业科学家以及患者群体代表组成。专家小组将审查这些指南，并随着新科学证据的出现每年进行更新。
